Re-posted from Yahoo News:
The NYU Langone Medical Center’s Cancer Institute recently purchased a highly advanced molecular analysis system for cancer research with funds donated by the New York mesothelioma lawyers of Belluck & Fox, LLP.
The NanoString Technologies nCounter Analysis System is a fully automated, multi-application digital detection and counting system that provides assays for gene expression, miRNA analysis and copy number variation. It has been employed in basic and translational research of cancer, metabolic disease, infectious disease and more since it was first introduced in 2008.
Scientists and other researchers at the Institute work to understand how cancer develops at the molecular level, and how to use knowledge about how cancer develops to reduce the risk of cancer and treat the disease. The Institute also offers a full continuum of personalized cancer care, from prevention through diagnosis, treatment and post-treatment support.
New York mesothelioma attorney Joseph W. Belluck, a founding partner of Belluck & Fox, said the firm was inspired to make a donation to the Langone Cancer Institute by the work of the Institute’s Dr. Harvey Pass.
“We’re excited that, with this purchase, Dr. Pass and his colleagues can obtain faster results as they seek the clues to better treatments and, one day, a cure for mesothelioma,” Belluck said.
“Dr. Pass has treated many of our clients and is one of our heroes. We know he is fighting for a cure and for our clients.”
Harvey I. Pass, MD is Professor of Cardiothoracic Surgery and Surgery, Director of Surgical Research, and Division Chief for Thoracic Surgery and Thoracic Oncology for the NYU School of Medicine. Pass is also an esteemed author of the Jones & Bartlett Learning patient education title, 100 Questions & Answers About Mesothelioma.
He is internationally recognized as an expert in the multidisciplinary management of lung cancer, mesothelioma, esophageal cancer, and the management of pulmonary metastases. He is known for his development of novel clinical trials for the treatment of thoracic malignancies as well as building a strong translational component to his programs with benchwork investigations.